Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | ME3 | Q16798 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21625643 | 1.00 | CCR2 (0.47) | CCR2SIGMAR1RPS6KB1TRPV1TRPM8 | |
| SCHEMBL21624755 | 0.93 | SIGMAR1 (0.53) | CCR2SIGMAR1RPS6KB1GRIN2BAOC3 | |
| SCHEMBL21624756 | 0.93 | SIGMAR1 (0.53) | CCR2SIGMAR1RPS6KB1GRIN2BAOC3 | |
| SCHEMBL21624722 | 0.91 | ME3 (0.50) | CCR2SIGMAR1RPS6KB1GRIN2BAOC3 | |
| SCHEMBL21624714 | 0.91 | SIGMAR1 (0.46) | CCR2SIGMAR1RPS6KB1AOC3ACACB | |
| SCHEMBL21624710 | 0.91 | SIGMAR1 (0.46) | CCR2SIGMAR1RPS6KB1AOC3ACACB | |
| SCHEMBL21624725 | 0.91 | ME3 (0.50) | CCR2SIGMAR1RPS6KB1GRIN2BAOC3 | |
| SCHEMBL22499968 | 0.90 | RPS6KB1 (0.46) | CCR2SIGMAR1RPS6KB1GRIN2BAOC3 | |
| SCHEMBL21625664 | 0.89 | ME3 (0.46) | CCR2SIGMAR1RPS6KB1GRIN2BAOC3 | |
| SCHEMBL21625663 | 0.89 | ME3 (0.46) | CCR2SIGMAR1RPS6KB1GRIN2BAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | claimed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | claimed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | claimed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | claimed |
| WO-2020017569-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日本ケミファ株式会社 | 2020-01-23 | — | — | WO | claimed |
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020203610-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING RHEUMATOID ARTHRITIS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | disclosed |
| WO-2020203609-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | disclosed |
| WO-2020017569-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日本ケミファ株式会社 | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1H | CCR2 2397/4885SIGMAR1 732/4885RPS6KB1 1000/4885 |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | CCR2 2218/4885SIGMAR1 1981/4885RPS6KB1 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.